Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema

Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema

Background: Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had previously shown a partial response to other anti-VEGF injec...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Borchert, GA, Kiire, CA, Stone, NM, Akil, H, Gkika, T, Fischer, MD, Xue, K, Cehajic-Kapetanovic, J, MacLaren, RE, Charbel Issa, P, Downes, SM, De Silva, SR
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	Springer Nature [academic journals on nature.com] 2024

समान संसाधन

Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy
द्वारा: Borchert, GA, और अन्य
प्रकाशित: (2024)

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
द्वारा: Helene O. Larsen, और अन्य
प्रकाशित: (2023-07-01)

Two-wavelength fundus autofluorescence and macular pigment optical density imaging in diabetic macular oedema.
द्वारा: Waldstein, S, और अन्य
प्रकाशित: (2012)

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
द्वारा: Lorenzo Ferro Desideri, और अन्य
प्रकाशित: (2023-05-01)

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
द्वारा: Hang A, और अन्य
प्रकाशित: (2024-12-01)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
द्वारा: Rush RB, और अन्य
प्रकाशित: (2022-12-01)

Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
द्वारा: Quah NQX, और अन्य
प्रकाशित: (2024-05-01)

Eligibility for faricimab in a real-world diabetic macular oedema population: a cross-sectional study
द्वारा: Helena Norberg, और अन्य
प्रकाशित: (2025-02-01)

Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
द्वारा: Christian Bührer, और अन्य
प्रकाशित: (2024-06-01)

Outcomes After Switching to Faricimab for Refractive Macular Edema in Treatment-Experienced Eyes with Neovascular Age-Related Macular Degeneration
द्वारा: Qaseem Y, और अन्य
प्रकाशित: (2024-10-01)

Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy
द्वारा: Grace A. Borchert, और अन्य
प्रकाशित: (2024-07-01)

Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
द्वारा: Yusuke Kikuchi, PhD, और अन्य
प्रकाशित: (2024-03-01)

Diabetic macular oedema: under‐represented in the genetic analysis of diabetic retinopathy
द्वारा: Broadgate, S, और अन्य
प्रकाशित: (2018)

CDHR1-related late-onset macular dystrophy: further insights
द्वारा: Yusuf, IH, और अन्य
प्रकाशित: (2020)

Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia
द्वारा: Daniel Samacá-Samacá, और अन्य
प्रकाशित: (2025-03-01)

Persistent macular oedema following Best vitelliform macular dystrophy undergoing anti-VEGF treatment
द्वारा: Tie-Zhu Lin, और अन्य
प्रकाशित: (2022-05-01)

Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration
द्वारा: Benjamin Ng, और अन्य
प्रकाशित: (2024-01-01)

Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration
द्वारा: Franziska Eckardt, और अन्य
प्रकाशित: (2024-04-01)

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
द्वारा: Leung EH, और अन्य
प्रकाशित: (2023-05-01)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
द्वारा: Rush RB
प्रकाशित: (2023-08-01)

The Role of Inflammation in Age-Related Macular Degeneration—Therapeutic Landscapes in Geographic Atrophy
द्वारा: Grace A. Borchert, और अन्य
प्रकाशित: (2023-08-01)

Faricimab for Treatment-Resistant Diabetic Macular Edema
द्वारा: Rush RB, और अन्य
प्रकाशित: (2022-08-01)

Cystoid macular oedema
द्वारा: Singh Daljit
प्रकाशित: (1983-01-01)

Cystoid macular oedema
द्वारा: Natarajan Mathivanan, और अन्य
प्रकाशित: (1984-01-01)

Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison
द्वारा: Carlotta Galeone, और अन्य
प्रकाशित: (2024-12-01)

Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review
द्वारा: Nasratullah Nasimi, और अन्य
प्रकाशित: (2024-07-01)

Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept
द्वारा: Akira Machida, और अन्य
प्रकाशित: (2024-04-01)

First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration
द्वारा: Wissam Aljundi, और अन्य
प्रकाशित: (2024-03-01)

Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)
द्वारा: Ermete Giancipoli, और अन्य
प्रकाशित: (2024-06-01)

Dynamics of Treatment Response to Faricimab for Diabetic Macular Edema
द्वारा: Katrin Fasler, और अन्य
प्रकाशित: (2024-09-01)

Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis
द्वारा: Francisco Rodríguez, और अन्य
प्रकाशित: (2024-05-01)

Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population
द्वारा: Farah N. I. Ibrahim, और अन्य
प्रकाशित: (2024-01-01)

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
द्वारा: Giuseppe Cancian, और अन्य
प्रकाशित: (2024-09-01)

Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration
द्वारा: Tanaka A, और अन्य
प्रकाशित: (2024-02-01)

Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis
द्वारा: Wei-Ting Yen, और अन्य
प्रकाशित: (2024-01-01)

Macular Thickness- An Early Predictor of Diabetic Macular Oedema
द्वारा: Chandrika Sareddy, और अन्य
प्रकाशित: (2022-05-01)

Gene therapy for age-related macular degeneration
द्वारा: MacLaren, RE
प्रकाशित: (2015)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
द्वारा: Henrik Faatz, और अन्य
प्रकाशित: (2022-11-01)

Evaluating Faricimab in Treatment-Naive Neovascular Age Related Macular Degeneration: A Retrospective Analysis of Real-World Data
द्वारा: Modeste D, और अन्य
प्रकाशित: (2024-10-01)

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study
द्वारा: Gabriela Grimaldi, और अन्य
प्रकाशित: (2024-09-01)